FDA Approves Glasdegib for Patients With Newly Diagnosed AML Who Cannot Undergo Intensive Chemotherapy

Based on the results of the phase III BRIGHT 1003 trial, the hedgehog inhibitor glasdegib is now FDA approved in combination with low-dose cytarabine for patients with acute myeloid leukemia age 75 years and older or those who cannot receive the standard intensive chemotherapy because of its toxicities.

The ASCO Post